168 related articles for article (PubMed ID: 27651514)
1. Oral Abuse Potential, Pharmacokinetics, and Safety of Once-Daily, Single-Entity, Extended-Release Hydrocodone (HYD) in Recreational Opioid Users.
Harris SC; Cipriano A; Colucci SV; Kapil RP; Geoffroy P; Hopyan T; Levy-Cooperman N
Pain Med; 2017 Jul; 18(7):1278-1291. PubMed ID: 27651514
[TBL] [Abstract][Full Text] [Related]
2. Intranasal Abuse Potential, Pharmacokinetics, and Safety of Once-Daily, Single-Entity, Extended-Release Hydrocodone (HYD) in Recreational Opioid Users.
Harris SC; Cipriano A; Colucci SV; Kapil RP; Geoffroy P; Hopyan T; Levy-Cooperman N
Pain Med; 2016 May; 17(5):820-31. PubMed ID: 26814240
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the Relative Intranasal Abuse Potential of a Hydrocodone Extended-Release Tablet Formulated with Abuse-Deterrence Technology in Nondependent, Recreational Opioid Users.
Bond M; Schoedel KA; Rabinovich-Guilatt L; Gasior M; Tracewell W; Malamut R; Ma Y; Webster LR
Pain Med; 2018 Aug; 19(8):1597-1612. PubMed ID: 29016880
[TBL] [Abstract][Full Text] [Related]
4. Abuse Potential with Oral Route of Administration of a Hydrocodone Extended-Release Tablet Formulated with Abuse-Deterrence Technology in Nondependent, Recreational Opioid Users.
Darwish M; Bond M; Ma Y; Tracewell W; Robertson P; Webster LR
Pain Med; 2017 Jan; 18(1):61-77. PubMed ID: 27330154
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic and Pharmacodynamic Correlations From 2 Studies Evaluating Abuse Potential of Hydrocodone Extended-Release Tablets.
Schoedel KA; Gillespie M; Levy-Cooperman N; Shram MJ; Rabinovich-Guilatt L
Clin Pharmacol Drug Dev; 2019 Jan; 8(1):32-39. PubMed ID: 29723441
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic Profile and Sustained 24-hour Analgesia of a Once-daily Hydrocodone Bitartrate Extended-release Tablet with Abuse-deterrent Properties.
Kapil RP; Cipriano A; Wen W; Yu Lynch S; He E; Colucci SV; Harris SC
Clin Ther; 2016 Feb; 38(2):302-14. PubMed ID: 26749219
[TBL] [Abstract][Full Text] [Related]
7. Human abuse potential of immediate-release/extended-release versus immediate-release hydrocodone bitartrate/acetaminophen: a randomized controlled trial in recreational users of prescription opioids.
Devarakonda K; Kostenbader K; Zheng Y; Montgomery JB; Barrett T; Young JL; Webster LR
Postgrad Med; 2015 Jan; 127(1):13-21. PubMed ID: 25584931
[TBL] [Abstract][Full Text] [Related]
8. Long-term safety and effectiveness of once-daily, single-entity, extended-release hydrocodone over 76 weeks of an open-label study in patients with chronic noncancer and nonneuropathic pain.
Taber L; Lynch SY; He E; Ripa SR
Postgrad Med; 2016 Jan; 128(1):23-33. PubMed ID: 26681111
[TBL] [Abstract][Full Text] [Related]
9. Human Abuse Potential of an Abuse-Deterrent (AD), Extended-Release (ER) Morphine Product Candidate (Morphine-ADER Injection-Molded Tablets) vs Extended-Release Morphine Administered Intranasally in Nondependent Recreational Opioid Users.
Webster LR; Smith MD; Lawler J; Lindhardt K; Dayno JM
Pain Med; 2017 Sep; 18(9):1695-1705. PubMed ID: 27651510
[TBL] [Abstract][Full Text] [Related]
10. Relative Bioavailability, Intranasal Abuse Potential, and Safety of Benzhydrocodone/Acetaminophen Compared with Hydrocodone Bitartrate/Acetaminophen in Recreational Drug Abusers.
Guenther SM; Mickle TC; Barrett AC; Roupe KA; Zhou J; Lam V
Pain Med; 2018 May; 19(5):955-966. PubMed ID: 29025138
[TBL] [Abstract][Full Text] [Related]
11. Human Abuse Potential of an Abuse-Deterrent (AD), Extended-Release (ER) Morphine Product Candidate (Morphine-ADER Injection-Molded Tablets) versus Extended-Release Morphine Administered Orally in Nondependent Recreational Opioid Users.
Smith MD; Webster LR; Lawler J; Lindhardt K; Dayno JM
Pain Med; 2017 May; 18(5):898-907. PubMed ID: 27633773
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of hydrocodone extended-release tablets formulated with different levels of coating to achieve abuse deterrence compared with a hydrocodone immediate-release/acetaminophen tablet in healthy subjects.
Darwish M; Bond M; Tracewell W; Robertson P; Yang R
Clin Drug Investig; 2015 Jan; 35(1):13-22. PubMed ID: 25391549
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the oral human abuse potential of Oxycodone DETERx® formulation (Xtampza® ER).
Meske D; Kopecky EA; Passik S; Shram MJ
J Opioid Manag; 2018; 14(5):359-372. PubMed ID: 30387859
[TBL] [Abstract][Full Text] [Related]
14. 12-Month safety and effectiveness of once-daily hydrocodone tablets formulated with abuse-deterrent properties in patients with moderate to severe chronic pain.
Wen W; Taber L; Lynch SY; He E; Ripa S
J Opioid Manag; 2015; 11(4):339-56. PubMed ID: 26312961
[TBL] [Abstract][Full Text] [Related]
15. Intranasal abuse potential of an abuse-deterrent oxycodone formulation compared to oxycodone immediate release and placebo in nondependent, recreational opioid users.
Setnik B; Schoedel K; Bartlett C; Dick C; Hakim N; Geoffroy P
J Opioid Manag; 2017; 13(6):449-464. PubMed ID: 29308591
[TBL] [Abstract][Full Text] [Related]
16. Assessment of pharmacodynamic effects following oral administration of crushed morphine sulfate and naltrexone hydrochloride extended-release capsules compared with crushed morphine sulfate controlled-release tablets and placebo in nondependent recreational opioid users.
Setnik B; Sommerville K; Goli V; Han L; Webster L
Pain Med; 2013 Aug; 14(8):1173-86. PubMed ID: 23745947
[TBL] [Abstract][Full Text] [Related]
17. Oral Human Abuse Potential of Oxycodone DETERx
Kopecky EA; Fleming AB; Levy-Cooperman N; O'Connor M; M Sellers E
J Clin Pharmacol; 2017 Apr; 57(4):500-512. PubMed ID: 27669664
[TBL] [Abstract][Full Text] [Related]
18. Single- and multiple-dose pharmacokinetics of a hydrocodone bitartrate extended-release tablet formulated with abuse-deterrence technology in healthy, naltrexone-blocked volunteers.
Darwish M; Yang R; Tracewell W; Robertson P; Bond M
Clin Ther; 2015 Feb; 37(2):390-401. PubMed ID: 25542074
[TBL] [Abstract][Full Text] [Related]
19. Effects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended-release hydrocodone tablet.
Kapil RP; Friedman K; Cipriano A; Michels G; Shet M; Mondal SA; Harris SC
Clin Ther; 2015 Oct; 37(10):2286-96. PubMed ID: 26350273
[TBL] [Abstract][Full Text] [Related]
20. Abuse Potential Study of ALO-02 (Extended-Release Oxycodone Surrounding Sequestered Naltrexone) Compared with Immediate-Release Oxycodone Administered Orally to Nondependent Recreational Opioid Users.
Setnik B; Bass A; Bramson C; Levy-Cooperman N; Malhotra B; Matschke K; Geoffroy P; Sommerville KW; Wolfram G
Pain Med; 2017 Jun; 18(6):1077-1088. PubMed ID: 27550954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]